https://www.revisiontx.com/ourmission daily 0.75 2024-01-02 https://images.squarespace-cdn.com/content/v1/5c1d498312b13f922f890fe7/1550719766431-SULFWGA91ILN67EFGY3D/Girl-behind-phoropter.jpg About - Commitment to Patients Each ophthalmic medicine reVision develops addresses an unmet or poorly met need, irrespective of that medicine’s potential to offer traditional patent or pricing exclusivity. https://images.squarespace-cdn.com/content/v1/5c1d498312b13f922f890fe7/1551659675021-T4UPF8GFT65CORI3IOPW/doctor-shakes-hands.png About - Commitment to Change By finding a new way to commercialize, reVision seeks to improve the drug price paradigm through free market competitive pressure, shifting the debate on drug costs away from imposing price controls and undermining patents and innovation. https://images.squarespace-cdn.com/content/v1/5c1d498312b13f922f890fe7/1550721337035-T4PTJHE765L1IFNKJUNM/pills-in-petri-dish.jpg About - Commitment to Access reVision reduces development cost by repositioning existing products and passes this saving directly to the consumers via lower cost and simplified access. reVision’s unique adoption model seeks patient, doctor, and payer commitments during development to facilitate early product adoption in return for prices that encourage access. https://images.squarespace-cdn.com/content/v1/5c1d498312b13f922f890fe7/1d6c727d-98bf-4618-b738-651cd402d337/Background.png About - Develop ophthalmic products to treat inadequately met needs for high-impact diseases. https://images.squarespace-cdn.com/content/v1/5c1d498312b13f922f890fe7/1d6c727d-98bf-4618-b738-651cd402d337/Background.png About - Reduce cost by securing stakeholder support for development and commercialization. https://images.squarespace-cdn.com/content/v1/5c1d498312b13f922f890fe7/1d6c727d-98bf-4618-b738-651cd402d337/Background.png About - Mitigate risk by repositioning existing products: we repurpose approved drugs and rescue shelved drugs. https://images.squarespace-cdn.com/content/v1/5c1d498312b13f922f890fe7/1d6c727d-98bf-4618-b738-651cd402d337/Background.png About - Expand accessibility by passing cost savings to consumers to ensure sustainable business. https://images.squarespace-cdn.com/content/v1/5c1d498312b13f922f890fe7/1644266699352-F5QQNZJ1RO0WUCD7FBV2/Blue-square.jpg About - reVision Therapeutics Attends Stargardt’s Connected Community Zoom Oct 4, 2023 https://images.squarespace-cdn.com/content/v1/5c1d498312b13f922f890fe7/1644266579883-WPSKZ1BVY262AGG5HQ85/Blue-square.jpg About - Aequus and reVision to Collaborate on Stargardt Disease Program Aug 17, 2021 https://images.squarespace-cdn.com/content/v1/5c1d498312b13f922f890fe7/1644266671253-3WITGH7LZ6QWFHRY7777/Blue-square.jpg About - reVision Therapeutics Announces US FDA Grant of Rare Pediatric Disease and Orphan-Drug Designation Oct 28, 2020 https://images.squarespace-cdn.com/content/v1/5c1d498312b13f922f890fe7/1550721832998-UVFL89BA7CS4HQCPA7IZ/image-01-eye-931978-1920_hires.jpg About https://www.revisiontx.com/intro daily 1.0 2022-05-05 https://www.revisiontx.com/contact-us daily 0.75 2023-07-03 https://www.revisiontx.com/rev-0100 daily 0.75 2023-10-04 https://images.squarespace-cdn.com/content/v1/5c1d498312b13f922f890fe7/1688648781557-HKK9IZCIU6CLR3RHO9M2/image-asset.jpeg REV-0100 - REV-0100 is unique… Other products in development to treat Stargardt disease have different mechanisms of action, some of which may retard the visual cycle, which may negatively impact vision. REV-0100 works differently, clearing the toxic lipid without impact on the visual cycle. https://images.squarespace-cdn.com/content/v1/5c1d498312b13f922f890fe7/045be34d-6bb6-48ed-8760-81f7d91587a9/Stargardt-disease-summary-slide.png REV-0100 https://images.squarespace-cdn.com/content/v1/5c1d498312b13f922f890fe7/279a1abb-560e-4c37-904b-a2011b2fe34b/Indication+Comparison.png REV-0100 https://images.squarespace-cdn.com/content/v1/5c1d498312b13f922f890fe7/1688648811080-CDEPISOUGDEM4848T31B/image-asset.jpeg REV-0100 - REV-0100 is versatile… Because REV-0100 works by clearing toxic lipids, it is being considered for multiple uses. It may be effective as a first-line monotherapy, adjuvant treatment in combination with other oral therapies, or as a temporary treatment prior to or during such as gene therapy. https://www.revisiontx.com/investor-overview daily 0.75 2023-10-05 https://images.squarespace-cdn.com/content/v1/5c1d498312b13f922f890fe7/1644262583244-KQ9AMBL8D1O8Y0219RVI/blue-square.jpg Investor Information - reVision Therapeutics Announces US FDA Grant of Rare Pediatric Disease and Orphan-Drug Designation Oct 28, 2020 https://images.squarespace-cdn.com/content/v1/5c1d498312b13f922f890fe7/1644262571445-ESAVOVEN7YW175LRLIL5/blue-square.jpg Investor Information - Aequus and reVision to Collaborate on Stargardt Disease Program Aug 17, 2021 https://images.squarespace-cdn.com/content/v1/5c1d498312b13f922f890fe7/1644262594111-LJVUZAFZON4TQLCQTW90/blue-square.jpg Investor Information - reVision Therapeutics Attends Stargardt’s Connected Community Zoom Oct 4, 2023 https://images.squarespace-cdn.com/content/v1/5c1d498312b13f922f890fe7/1644262468690-S7KBGO193BKOXA8LUZZ2/blue-green-iris.jpg Investor Information - Investor Overview reVision Therapeutics Inc. is a preclinical-stage pharmaceutical company pioneering ophthalmic therapies and dedicated to the repurposing, development, and commercialization of generally recognized as safe (GRAS) drugs directed against ophthalmic disease and disorders for the treatment of Stargardt disease, dry age-related macular degeneration, dry eye disease, and proliferative vitreoretinopathy. reVision's lead candidate REV-0100 functions by sequestering and removing the toxic lipid-bisretinoid, such as A2E. reVision's lead compound was awarded both Orphan Drug Designation (ODD) and Rare Pediatric Disease (RPD) designation by the US Food and Drug Administration. https://www.revisiontx.com/stargardt-disease daily 0.75 2023-08-14 https://images.squarespace-cdn.com/content/v1/5c1d498312b13f922f890fe7/cb2116db-ce8f-4211-bfbc-287081fc3724/Stargardt-Vision-Stock-Photo.png Stargardt Disease - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5c1d498312b13f922f890fe7/1643660100919-OF07X1MO9MQUEZFSWFGH/man-eye-pain.jpg Stargardt Disease - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5c1d498312b13f922f890fe7/1550715631366-6M5SV80YKR8XP4G1H9KE/reVision-Therapeutics-favicon.png Stargardt Disease - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.revisiontx.com/dry-eye-disease-therapy daily 0.75 2022-09-06 https://images.squarespace-cdn.com/content/v1/5c1d498312b13f922f890fe7/279a1abb-560e-4c37-904b-a2011b2fe34b/Indication+Comparison.png Dry Eye Disease Therapy - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.revisiontx.com/proliferative-vitreoretinopathy daily 0.75 2023-07-13 https://images.squarespace-cdn.com/content/v1/5c1d498312b13f922f890fe7/1550715631366-6M5SV80YKR8XP4G1H9KE/reVision-Therapeutics-favicon.png Proliferative Vitreoretinopathy - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5c1d498312b13f922f890fe7/1555093272977-8ESNE8BL4Y3HDO7ZCOGA/pvr.png Proliferative Vitreoretinopathy - Make it stand out Figure 1. A typical example of a fixed “star fold” preoperatively. https://images.squarespace-cdn.com/content/v1/5c1d498312b13f922f890fe7/c1cb9209-471d-4ed3-aff2-c54ee58e4085/Floaters.jpeg Proliferative Vitreoretinopathy - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.revisiontx.com/dry-eye-disease daily 0.75 2023-06-30 https://images.squarespace-cdn.com/content/v1/5c1d498312b13f922f890fe7/1643826124725-XP6KKADWVU6XAH70L7B9/blurred-public-transport.jpg Dry Eye Disease - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5c1d498312b13f922f890fe7/e64f540b-df12-4347-8dfc-839d234052a3/stock-photo-red-eye.jpeg Dry Eye Disease - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5c1d498312b13f922f890fe7/1550715631366-6M5SV80YKR8XP4G1H9KE/reVision-Therapeutics-favicon.png Dry Eye Disease - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.revisiontx.com/press-releases daily 0.75 2023-10-04 https://images.squarespace-cdn.com/content/v1/5c1d498312b13f922f890fe7/1550715631366-6M5SV80YKR8XP4G1H9KE/reVisionTherapeutics.favicon.png Press Releases https://images.squarespace-cdn.com/content/v1/5c1d498312b13f922f890fe7/1550715631366-6M5SV80YKR8XP4G1H9KE/reVisionTherapeutics.favicon.png Press Releases https://images.squarespace-cdn.com/content/v1/5c1d498312b13f922f890fe7/1550715631366-6M5SV80YKR8XP4G1H9KE/reVisionTherapeutics.favicon.png Press Releases - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5c1d498312b13f922f890fe7/1550715631366-6M5SV80YKR8XP4G1H9KE/reVisionTherapeutics.favicon.png Press Releases - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5c1d498312b13f922f890fe7/1550715631366-6M5SV80YKR8XP4G1H9KE/reVisionTherapeutics.favicon.png Press Releases https://images.squarespace-cdn.com/content/v1/5c1d498312b13f922f890fe7/1550715631366-6M5SV80YKR8XP4G1H9KE/reVisionTherapeutics.favicon.png Press Releases - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.revisiontx.com/bio-europe-2018 daily 0.75 2023-07-13 https://www.revisiontx.com/winner-audience-award2018 daily 0.75 2022-02-01 https://www.revisiontx.com/revision-therapeutics-announces-license-with-cornell daily 0.75 2022-02-01 https://www.revisiontx.com/revision-fda-grant2020 daily 0.75 2022-02-01 https://www.revisiontx.com/aequus-and-revision-collaborate-on-stargardt-program daily 0.75 2022-02-01 https://www.revisiontx.com/proliferative-vitreoretinopathy-therapy daily 0.75 2023-07-13 https://images.squarespace-cdn.com/content/v1/5c1d498312b13f922f890fe7/279a1abb-560e-4c37-904b-a2011b2fe34b/Indication+Comparison.png Proliferative Vitreoretinopathy Therapy https://www.revisiontx.com/terms-of-service daily 0.75 2023-06-27 https://www.revisiontx.com/privacy-policy daily 0.75 2023-06-27 https://www.revisiontx.com/dry-amd daily 0.75 2023-08-14 https://images.squarespace-cdn.com/content/v1/5c1d498312b13f922f890fe7/1550715631366-6M5SV80YKR8XP4G1H9KE/reVision-Therapeutics-favicon.png Dry AMD - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5c1d498312b13f922f890fe7/dd724ef4-705a-4b5a-a756-b83b65f46c86/Dry+AMD+Vision.png Dry AMD - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.revisiontx.com/scientific-advisory-board daily 0.75 2023-04-27 https://www.revisiontx.com/management-team daily 0.75 2024-01-22 https://images.squarespace-cdn.com/content/v1/5c1d498312b13f922f890fe7/9fb0d71a-97b5-4b4e-a4d7-a38999580b23/Valentina+Dallacasagrande_Square.jpg Management Team - Valentina Dallacasagrande, Ph.D. Co-Founder and Sr. Scientific Advisor https://images.squarespace-cdn.com/content/v1/5c1d498312b13f922f890fe7/a0472a74-8aec-401d-8bae-d96e20a92729/Chaitanya+Badwe_Color+SQ.jpg Management Team - Chaitanya Badwe, Ph.D. Co-Founder and Sr. Business Advisor https://images.squarespace-cdn.com/content/v1/5c1d498312b13f922f890fe7/0d6dc5d8-06bb-4300-9ffe-f61ee0a18769/Paul+Fehlner_Color+%5BUpdated%5D+SQ.jpg Management Team - Paul Fehlner, Ph.D., JD Paul Fehlner, Ph.D., JD https://www.revisiontx.com/executive-advisors daily 0.75 2023-07-06 https://images.squarespace-cdn.com/content/v1/5c1d498312b13f922f890fe7/25ac4389-fa7a-4bec-8d58-be16be228fa9/Houman+Hemmati_Color.jpg Executive Advisors - Houman David Hemmati, MD, Ph.D. Medical Advisor https://images.squarespace-cdn.com/content/v1/5c1d498312b13f922f890fe7/edf933e2-4313-4a8c-9a69-26fc2573e172/Kathryn+Gregory_Color.jpeg Executive Advisors - Kathryn Gregory, MBA Executive Advisor & Chief Business Officer https://www.revisiontx.com/recently-diagnosed-patients daily 0.75 2023-07-13 https://www.revisiontx.com/revision-therapeutics-attends-stargardts-connected-community-zoom daily 0.75 2023-10-04